<!DOCTYPE html>
<html lang="en-us">

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
    
    
    
  
  

  

  
  
  
    
  
  <meta name="description" content="The potential consequences of a major radiological event are not only large-scale external radiation exposure of the population, but also uncontrolled dissemination of, and internal contamination with, radionuclides. When planning an emergency response to radiological and nuclear incidents, one must consider the need for not only post-exposure treatment for contaminated individuals, but also prophylactic measures to protect the workforce facing contaminated areas and patients in the aftermath of such events. In addition to meeting the desired criteria for post-exposure treatments such as safety, ease of administration, and broad-spectrum efficacy against multiple radionuclides and levels of challenge, ideal prophylactic countermeasures must include rapid onset; induce minimal to no performance-decrementing side effects; be compatible with current military Chemical, Biological, Radiological, Nuclear, and Explosive countermeasures; and require minimal logistical burdens. Hydroxypyridinone-based actinide decorporation agents have shown the most promise as decorporation strategies for various radionuclides of concern, including the actinides plutonium and americium. The studies presented here probe the extent of plutonium decorporation efficacy for two chelating agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), from early pre-exposure time points to a delay of up to 7 days in parenteral or oral treatment administration, i.e., well beyond the initial hours of emergency response. Despite delayed treatment after a contamination event, both ligands clearly enhanced plutonium elimination through the investigated 7-day post-treatment period. In addition, a remarkable prophylactic efficacy was revealed for 3,4,3-LI(1,2-HOPO) with treatment as early as 48??h before the plutonium challenge. This work provides new perspectives in the indication and use of experimental actinide decorporation treatments.">

  
  <link rel="alternate" hreflang="en-us" href="https://julianrees.github.io/webdemo/publication/an-early-2017/">

  


  
  
  
  <meta name="theme-color" content="#6baed6">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    

    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.css" integrity="sha256-SHMGCYmST46SoyGgo4YR/9AlK1vf3ff84Aq9yK4hdqM=" crossorigin="anonymous">
    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono%7CMuli:400,700%7CRaleway%7CAnton%7CComfortaa:700%7CCatamaran:700&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/webdemo/css/academic.css">

  




  


  

  <link rel="manifest" href="/webdemo/index.webmanifest">
  <link rel="icon" type="image/png" href="/webdemo/images/icon_hu7e26b4628f129972ef79540a0bb720d6_10659_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/webdemo/images/icon_hu7e26b4628f129972ef79540a0bb720d6_10659_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="https://julianrees.github.io/webdemo/publication/an-early-2017/">

  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="HOPO Therapeutics">
  <meta property="og:url" content="https://julianrees.github.io/webdemo/publication/an-early-2017/">
  <meta property="og:title" content="From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents | HOPO Therapeutics">
  <meta property="og:description" content="The potential consequences of a major radiological event are not only large-scale external radiation exposure of the population, but also uncontrolled dissemination of, and internal contamination with, radionuclides. When planning an emergency response to radiological and nuclear incidents, one must consider the need for not only post-exposure treatment for contaminated individuals, but also prophylactic measures to protect the workforce facing contaminated areas and patients in the aftermath of such events. In addition to meeting the desired criteria for post-exposure treatments such as safety, ease of administration, and broad-spectrum efficacy against multiple radionuclides and levels of challenge, ideal prophylactic countermeasures must include rapid onset; induce minimal to no performance-decrementing side effects; be compatible with current military Chemical, Biological, Radiological, Nuclear, and Explosive countermeasures; and require minimal logistical burdens. Hydroxypyridinone-based actinide decorporation agents have shown the most promise as decorporation strategies for various radionuclides of concern, including the actinides plutonium and americium. The studies presented here probe the extent of plutonium decorporation efficacy for two chelating agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), from early pre-exposure time points to a delay of up to 7 days in parenteral or oral treatment administration, i.e., well beyond the initial hours of emergency response. Despite delayed treatment after a contamination event, both ligands clearly enhanced plutonium elimination through the investigated 7-day post-treatment period. In addition, a remarkable prophylactic efficacy was revealed for 3,4,3-LI(1,2-HOPO) with treatment as early as 48??h before the plutonium challenge. This work provides new perspectives in the indication and use of experimental actinide decorporation treatments."><meta property="og:image" content="img/map[gravatar:%!s(bool=false) shape:square]">
  <meta property="twitter:image" content="img/map[gravatar:%!s(bool=false) shape:square]"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2020-04-05T05:18:33&#43;00:00">
    
    <meta property="article:modified_time" content="2017-04-01T00:00:00&#43;00:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://julianrees.github.io/webdemo/publication/an-early-2017/"
  },
  "headline": "From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents",
  
  "datePublished": "2020-04-05T05:18:33Z",
  "dateModified": "2017-04-01T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "Dahlia D. An"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "HOPO Therapeutics",
    "logo": {
      "@type": "ImageObject",
      "url": "https://julianrees.github.io/webdemo/images/icon_hu7e26b4628f129972ef79540a0bb720d6_10659_192x192_fill_lanczos_center_2.png"
    }
  },
  "description": "The potential consequences of a major radiological event are not only large-scale external radiation exposure of the population, but also uncontrolled dissemination of, and internal contamination with, radionuclides. When planning an emergency response to radiological and nuclear incidents, one must consider the need for not only post-exposure treatment for contaminated individuals, but also prophylactic measures to protect the workforce facing contaminated areas and patients in the aftermath of such events. In addition to meeting the desired criteria for post-exposure treatments such as safety, ease of administration, and broad-spectrum efficacy against multiple radionuclides and levels of challenge, ideal prophylactic countermeasures must include rapid onset; induce minimal to no performance-decrementing side effects; be compatible with current military Chemical, Biological, Radiological, Nuclear, and Explosive countermeasures; and require minimal logistical burdens. Hydroxypyridinone-based actinide decorporation agents have shown the most promise as decorporation strategies for various radionuclides of concern, including the actinides plutonium and americium. The studies presented here probe the extent of plutonium decorporation efficacy for two chelating agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), from early pre-exposure time points to a delay of up to 7 days in parenteral or oral treatment administration, i.e., well beyond the initial hours of emergency response. Despite delayed treatment after a contamination event, both ligands clearly enhanced plutonium elimination through the investigated 7-day post-treatment period. In addition, a remarkable prophylactic efficacy was revealed for 3,4,3-LI(1,2-HOPO) with treatment as early as 48??h before the plutonium challenge. This work provides new perspectives in the indication and use of experimental actinide decorporation treatments."
}
</script>

  

  


  


  





  <title>From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents | HOPO Therapeutics</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/webdemo/">HOPO Therapeutics</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/webdemo/">HOPO Therapeutics</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-end" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/webdemo/#"><span>Home</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/webdemo/#posts"><span>News</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/webdemo/webdemo/science/"><span>Science</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/webdemo/webdemo/about/"><span>About</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/webdemo/#contact"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      

      

      

    </ul>

  </div>
</nav>


  <div class="pub">

  












  

  
  
  
<div class="article-container pt-3">
  <h1>From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  
  <span>Dahlia D. An</span>, <span>Birgitta Kullgren</span>, <span>Erin E. Jarvis</span>, <span>Rebecca J. Abergel</span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    April 2017
  </span>
  

  

  

  
  
  

  
  

</div>

    











  



<div class="btn-links mb-3">
  
  








  
    
  



<a class="btn btn-outline-primary my-1 mr-1" href="http://dx.doi.org/10.1016/j.cbi.2016.03.034%20http://linkinghub.elsevier.com/retrieve/pii/S000927971630103X" target="_blank" rel="noopener">
  PDF
</a>



<button type="button" class="btn btn-outline-primary my-1 mr-1 js-cite-modal"
        data-filename="/webdemo/publication/an-early-2017/cite.bib">
  Cite
</button>













<a class="btn btn-outline-primary my-1 mr-1" href="https://doi.org/10.1016/j.cbi.2016.03.034" target="_blank" rel="noopener">
  DOI
</a>



</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">The potential consequences of a major radiological event are not only large-scale external radiation exposure of the population, but also uncontrolled dissemination of, and internal contamination with, radionuclides. When planning an emergency response to radiological and nuclear incidents, one must consider the need for not only post-exposure treatment for contaminated individuals, but also prophylactic measures to protect the workforce facing contaminated areas and patients in the aftermath of such events. In addition to meeting the desired criteria for post-exposure treatments such as safety, ease of administration, and broad-spectrum efficacy against multiple radionuclides and levels of challenge, ideal prophylactic countermeasures must include rapid onset; induce minimal to no performance-decrementing side effects; be compatible with current military Chemical, Biological, Radiological, Nuclear, and Explosive countermeasures; and require minimal logistical burdens. Hydroxypyridinone-based actinide decorporation agents have shown the most promise as decorporation strategies for various radionuclides of concern, including the actinides plutonium and americium. The studies presented here probe the extent of plutonium decorporation efficacy for two chelating agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), from early pre-exposure time points to a delay of up to 7 days in parenteral or oral treatment administration, i.e., well beyond the initial hours of emergency response. Despite delayed treatment after a contamination event, both ligands clearly enhanced plutonium elimination through the investigated 7-day post-treatment period. In addition, a remarkable prophylactic efficacy was revealed for 3,4,3-LI(1,2-HOPO) with treatment as early as 48??h before the plutonium challenge. This work provides new perspectives in the indication and use of experimental actinide decorporation treatments.</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            
            <a href="/webdemo/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9"><em>Chemico-Biological Interactions</em></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    



<div class="article-tags">
  
  <a class="badge badge-light" href="/webdemo/tags/chelation-therapy/">Chelation therapy</a>
  
  <a class="badge badge-light" href="/webdemo/tags/contamination/">Contamination</a>
  
  <a class="badge badge-light" href="/webdemo/tags/medical-countermeasure/">Medical countermeasure</a>
  
  <a class="badge badge-light" href="/webdemo/tags/prophylaxis/">Prophylaxis</a>
  
  <a class="badge badge-light" href="/webdemo/tags/radionuclides/">Radionuclides</a>
  
</div>



<div class="share-box" aria-hidden="true">
  <ul class="share">
    
      
      
      
        
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=https://julianrees.github.io/webdemo/publication/an-early-2017/&amp;text=From%20early%20prophylaxis%20to%20delayed%20treatment:%20Establishing%20the%20plutonium%20decorporation%20activity%20window%20of%20hydroxypyridinonate%20chelating%20agents" target="_blank" rel="noopener" class="share-btn-twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=https://julianrees.github.io/webdemo/publication/an-early-2017/&amp;t=From%20early%20prophylaxis%20to%20delayed%20treatment:%20Establishing%20the%20plutonium%20decorporation%20activity%20window%20of%20hydroxypyridinonate%20chelating%20agents" target="_blank" rel="noopener" class="share-btn-facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="mailto:?subject=From%20early%20prophylaxis%20to%20delayed%20treatment:%20Establishing%20the%20plutonium%20decorporation%20activity%20window%20of%20hydroxypyridinonate%20chelating%20agents&amp;body=https://julianrees.github.io/webdemo/publication/an-early-2017/" target="_blank" rel="noopener" class="share-btn-email">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=https://julianrees.github.io/webdemo/publication/an-early-2017/&amp;title=From%20early%20prophylaxis%20to%20delayed%20treatment:%20Establishing%20the%20plutonium%20decorporation%20activity%20window%20of%20hydroxypyridinonate%20chelating%20agents" target="_blank" rel="noopener" class="share-btn-linkedin">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://web.whatsapp.com/send?text=From%20early%20prophylaxis%20to%20delayed%20treatment:%20Establishing%20the%20plutonium%20decorporation%20activity%20window%20of%20hydroxypyridinonate%20chelating%20agents%20https://julianrees.github.io/webdemo/publication/an-early-2017/" target="_blank" rel="noopener" class="share-btn-whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=https://julianrees.github.io/webdemo/publication/an-early-2017/&amp;title=From%20early%20prophylaxis%20to%20delayed%20treatment:%20Establishing%20the%20plutonium%20decorporation%20activity%20window%20of%20hydroxypyridinonate%20chelating%20agents" target="_blank" rel="noopener" class="share-btn-weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>












  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/webdemo/authors/dahlia-d.-an/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/webdemo/authors/birgitta-kullgren/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/webdemo/authors/erin-e.-jarvis/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/webdemo/authors/rebecca-j.-abergel/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  










  
  
  <div class="article-widget content-widget-hr">
    <h3>Related</h3>
    <ul>
      
      <li><a href="/webdemo/publication/choi-vitro-2015/">In Vitro Metabolism and Stability of the Actinide Chelating Agent 3,4,3-LI(1,2-HOPO)</a></li>
      
    </ul>
  </div>
  



  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      

    

    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.js" integrity="sha256-EErZamuLefUnbMBQbsEqu1USa+btR2oIlCpBJbyD4/g=" crossorigin="anonymous"></script>
    

    
    
    <script>const code_highlighting = false;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    

    
    

    

    
    

    
    

    
    

    
    
    
    
    
    
    
    
    
    
    
    
    <script src="/webdemo/js/academic.min.6f7ce8be710290b8c431bbc97f405d15.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/webdemo/privacy/">Privacy Policy</a>
    
    
       &middot; 
      <a href="/webdemo/terms/">Terms & Conditions</a>
    
  </p>
  

  <p class="powered-by">
    Â© 2020 HOPO Therapeutics, Inc. &middot; All Rights Reserved 

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
